Skip to content
Breathing, swallowing or vision problems: call the emergency services (15 or 112 in France).

Botox frown lines: why, how and for whom?

Frown lines, between the eyebrows, are the area for which every botulinum toxin approved for aesthetic use has an indication. In France, it is also the only area approved for both families of toxins, long-acting and short-acting. Here is what the official labels say, and what to discuss with your doctor.

Frown lines are one of the eleven areas covered by our "why and how" atlas of botulinum toxin. This page explains why they are treated, with which toxins, how quickly and with what risks. It does not replace your doctor’s advice.

Why are frown lines treated?

Frown lines are the vertical creases that deepen between the eyebrows when you frown. They are also called glabellar lines (the glabella is the smooth space between the two eyebrows), or sometimes "11 lines" because of their shape. They are formed by the repeated contraction of two groups of muscles: the corrugators, one on each side, which draw the eyebrows together, and the procerus, in the middle, which pulls them down. The labels describe injection into these very muscles: two points in each corrugator and one point in the procerus1.

Botulinum toxin temporarily relaxes these muscles. Frowning becomes less marked and the lines deepen less. The effect is not permanent: it fades as the nerve endings recover their function1.

Horizontal forehead lines and eyebrow position depend on other muscles. They have their own pages, on treating forehead lines and on lifting the eyebrows.

When is the toxin used?

The labels define the indication precisely: the temporary improvement of moderate to severe frown lines at maximum frown, when they have an important psychological impact, in adults1,2. It is therefore not a routine procedure: how much the lines bother you is part of the indication, and your doctor assesses it with you.

Some situations lead doctors not to treat. The labels contraindicate injection in case of allergy to the toxin or to a component of the product, a generalised disorder of the muscles and of the junction between nerve and muscle (myasthenia gravis, Lambert-Eaton syndrome), or an infection at the injection site1,2. Pregnancy and breastfeeding are among the situations in which treatment is not recommended1,2. Injection is not recommended in people with a history of swallowing difficulties1,2.

Which toxin for frown lines?

Approval status in France: Glabella (frown lines)
ToxinStatus in France
Long-acting botulinum toxin (type A)Approved for aesthetic use in this area (SmPC in force in France)
Short-acting botulinum toxin (serotype E)Approved for aesthetic use in this area (SmPC in force in France)

In France, frown lines are the only area approved for both families of toxins for aesthetic use1,2,3. All type A toxins approved for aesthetic use cover this indication2,4,5,7,8. The short-acting botulinum toxin (serotype E) has been approved in the European Union since 15 July 2026, for this indication only1,6. As of 29 September 2026, the date of the latest update consulted, it had no entry yet in the French public medicines database3.

Its status depends on the country. It was approved in Canada on 22 June 2026, for the same indication9.

The two families do not have the same profile: one works faster and for a shorter time, the other more slowly and for longer. Neither is better than the other, and no trial compares them directly. To understand what sets the new botulinum toxin apart, without ranking the two, see the dedicated page. The long-acting toxin remains the usual choice, in particular when you are looking for an effect lasting several months or for maintenance treatment.

Is it right for me?

No web page can answer this question for you. The points your doctor will assess are well known: how deep the lines are when you frown, how much they bother you, your medical history, your current treatments, any pregnancy plans, and what you expect in terms of how long the effect lasts.

Age matters too, with no simple rule. Several type A toxins are not indicated after 654,8, one up to 755. For the short-acting toxin, only 7% of trial patients were 65 or older, and their response rate on day 7 was lower1.

A few useful questions to ask your doctor: which toxin are you offering me, and why? How long should the effect last in my case? Which side effects should I watch for, and whom should I contact if they occur? When could I consider another session?

Onset and duration

With a type A toxin, first effects usually appear within 2–3 days, up to one week; the peak effect is reached between week 2 and week 4; it usually lasts 3–4 months2,4,5, up to 6 months depending on the product7. Sessions are at least 3 months apart4.

With the short-acting toxin, first effects appear from 8 hours, the peak effect is seen around day 7 and it usually lasts 2–3 weeks1. Its label provides for occasional use. A new injection less than 6 weeks after the previous one has not been evaluated, nor has a type A toxin injected less than 30 days afterwards1.

For more detail on these timelines, see how long botulinum toxin takes to work.

What are the risks in this area?

For this area, the labels describe drooping of the upper eyelid (eyelid ptosis), drooping of the eyebrow, or conversely an eyebrow arched upwards at its outer end, known as the "Mephisto sign"1,2. Headaches, eyelid swelling and injection-site reactions (redness, small bruise) are also described2. To limit the risk of ptosis, the label asks in particular to avoid injecting near the muscle that lifts the eyelid1: this is why the eyelid area is approached with caution. These effects are temporary. Published frequencies come from different trials and cannot be used to compare products.

The labels also point out that the effect of the toxin can, rarely, spread beyond the injection site: any difficulty swallowing, speaking or breathing requires immediate medical attention1,2.

If something unexpected happens, the page on what to do after frown line injections explains how to recognise it and when to see a doctor.

Key points

  • Frown lines are formed by the corrugator and procerus muscles, which the toxin temporarily relaxes1.
  • In France, this is the only area approved for both families of toxins1,3.
  • Long-acting toxin (type A): peak between week 2 and week 4, usually 3–4 months; short-acting toxin (serotype E): around day 7, 2–3 weeks1,2.
  • The short-acting toxin is approved in the EU and Canada (as of 9 October 2026)6,9.
  • The decision to treat, and the choice of toxin, are made during a consultation.

Frequently asked questions

  • Can frown lines be treated with the new botulinum toxin?

    Yes, where it is approved. Frown lines are the only approved indication of the short-acting toxin, in moderate to severe lines with an important psychological impact in adults: in the European Union since 15 July 2026 and in Canada since 22 June 20261,6,9. All type A toxins approved for aesthetic use cover this indication2,4,5,7,8. The choice between the two families is made during a consultation.

  • How long does treatment of frown lines last?

    It depends on the toxin. With a type A toxin, the effect usually lasts 3–4 months2,4, up to 6 months depending on the product7. With the short-acting toxin, it usually lasts 2–3 weeks1. In both cases the effect is temporary: the muscle gradually recovers its activity and the line deepens again when you frown.

  • Can frown lines be treated after 65?

    There is no single rule. Several type A toxins are not indicated after 654,8, one is indicated up to 755, and data on the short-acting toxin are limited in this age group, with lower response rates1. Your doctor will assess your situation during a consultation, taking your medical history into account.

  • What should I do if my eyelid droops after an injection between the eyebrows?

    A drooping upper eyelid is one of the side effects described for this area in the labels1,2. It is temporary. Talk to the doctor who performed the injection, and seek medical attention promptly if you notice a visual disturbance or difficulty swallowing or breathing. The page on what can happen after frown line injections details the signs to watch for.

Sources

  1. 1.Summary of product characteristics of the serotype E botulinum toxin approved in the European Union (EPAR annex I) (opens in a new tab) — European Commission (Union Register of medicinal products)
  2. 2.SmPC of a type A botulinum toxin approved for aesthetic use in France (BDPM, CIS 68150775) (opens in a new tab) — French public medicines database (BDPM)
  3. 3.French public medicines database: list of medicinal products (CIS file), updated 29 September 2026 (opens in a new tab) — French public medicines database (Ministry of Health)
  4. 4.SmPC of a type A botulinum toxin approved for aesthetic use in France (BDPM, CIS 66865211) (opens in a new tab) — French public medicines database (BDPM)
  5. 5.SmPC of a type A botulinum toxin approved for aesthetic use in France (BDPM, CIS 69878363) (opens in a new tab) — French public medicines database (BDPM)
  6. 6.European public assessment report (EPAR) of the serotype E botulinum toxin (opens in a new tab) — European Commission (Union Register of medicinal products)
  7. 7.SmPC of a type A botulinum toxin approved for aesthetic use in France (BDPM, CIS 69497348) (opens in a new tab) — French public medicines database (BDPM)
  8. 8.SmPC of a type A botulinum toxin approved for aesthetic use in France (BDPM, CIS 61592762) (opens in a new tab) — French public medicines database (BDPM)
  9. 9.Canadian product monograph of the serotype E botulinum toxin (authorization date: 2026-06-22) (opens in a new tab) — Health Canada
Book an appointmentSOS after an injection